Atharv Ability’s Delhi facility seeks to expand access to integrated, high-quality neuro-rehabilitation care in a region where such specialized services remain limited

This product would be manufactured at Lupin’s Nagpur facility in India

The product sales for Glycerol Phenylbutyrate Oral Liquid (RLD Ravicti) were $337 million for the year ended December 2025

This launch follows the receipt of approval for its ANDA from the USFDA

The inspection was conducted from April 13, 2026 to April 17, 2026

Lupin (Thailand) shall be engaged to import, market, promote, distribute and sell pharmaceutical products in Thailand

This launch follows the receipt of approval for its ANDA from the USFDA

The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg

The USFDA has approved Lupin’s Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labeling

This prestigious certification underscores the deep commitment and active participation of Lupin employees, whose voices were central to the evaluation

The transaction is expected to be completed by the end of May 2026, subject to certain closing conditions

The acquisition represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

The drug is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials

This product would be manufactured at Lupin’s Nagpur facility in India

This expansion reinforces LMS’s capability to consistently supply high-quality peptide building blocks, including protected amino acids

The agreement aims to expand access to innovative Semaglutide Injection with a patient-friendly reusable pen device in India

The Inspection was conducted from March 02, 2026 to March 07, 2026 and closed with the issuance of a Form-483 with two observations

The EIR was issued following an inspection of the facility from November 10 to November 21, 2025

Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the United States

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A

This strategic partnership combines Lupin’s strong commercial footprint in Canada

Topiramate Extended-Release Capsules has an estimated annual sale of $164 million in the U.S.

The product was developed in partnership with Pharmascience Inc

Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec

Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership

Under the terms of the agreement, the company will have exclusive rights to commercialize and distribute Bofanglutide in India

This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

The EIR was issued following an inspection of the facility from September 8 to September 16, 2025

These validations cover all three emission scopes - Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5 degree Celsius

This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market

This product would be manufactured at Lupin’s Pithampur facility in India

Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales

The product will be manufactured at the company’s Biotech facility in Pune, which was inspected by the USFDA prior to approval

The Inspection was conducted from November 10, 2025 to November 21, 2025 and closed with the issuance of a Form-483 with seven observations

The inspection was carried out from November 10 to November 14, 2025

Lupin is expanding the reach of its PrecisionSphere technology by fostering collaborations with companies looking to extend their product lifecycles

VITALYFE is a wellness platform designed for general health and lifestyle management

The company has received the EIR following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025

Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems

The company remains focused on improving the lives of its patients globally

The consolidated total income of the company increased by 24.89% at Rs 7,137.51 crore for Q2FY26

The facility manufactures metered dose inhalers, dry powder inhalers, topical formulations, and nasal solutions

VITALYFE uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalized, non-medical interventions that address the root causes of heart aging

Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders

The Inspection was conducted from September 29, 2025 to October 10, 2025, and concluded with one observation

The projected cumulative investment for the plant is $250 million

The inspection undertaken by USFDA at Lupin’s Pithampur Unit-2 manufacturing facility from July 8 to July 17, 2025

It is indicated as an adjunct to diet and exercise to improve glycemic control in adults

Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc

The product will be manufactured at the company’s Chhatrapati Sambhajinagar facility in India

The transaction is projected to close by the end of 2025, subject to certain closing conditions

This product would be manufactured at Lupin’s Nagpur facility in India

The inspection closed with four observations

The product will be manufactured at company’s Pithampur facility in India

The inspection closed with six observations

The inspection closed with two observations

This is the company’s first product using proprietary Nanomi B.V.’s (Nanomi) technology and has a 180-day CGT exclusivity

NATCO holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

The partnership is to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions

Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of $122 million in the U.S.

The total consolidated income of the company increased by 11.98% at Rs 6347.38 crore for Q1FY26

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

The inspection closed with the issuance of a Form-483 with four observations

LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs

The inspection closed with the issuance of a Form-483 with three observations

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc

The agreement is for commercialization of the company’s biosimilar Certolizumab Pegol

Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity

In terms of the BTA, the said transaction has been completed and transfer of API R&D Division is effective from July 01, 2025

In terms of the BTA, the said transaction has been completed, and transfer of OTC Business is effective from July 01, 2025

Prucalopride Tablets, 1 mg, and 2 mg had estimated annual sales of $184 million in the U.S.

This product will be manufactured at Lupin’s Goa facility in India

This partnership will enable Lupin to expand its footprint in China

This product would be manufactured at Lupin’s Nagpur facility in India

The companies have entered into agreement for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina

Honeywell Solstice Air has the potential to prevent the release of high global warming potential molecules

This product will be manufactured at Lupin’s Aurangabad facility in India

The total consolidated income of the company increased by 14.71% at Rs 5,724.08 crore for Q4FY25

The company holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity

Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company

The company initiated the Class II recall on April 18, 2025

This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services

The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024

With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary

This guide is based on the American College of Cardiology’s ‘Home-Based Care Workbook’

This award serves as a motivation to continue Nanomi’s mission to revolutionize healthcare

The company has incorporated wholly-owned subsidiary namely ‘Lupinlife Consumer Healthcare’

This product would be manufactured at Lupin’s Goa facility in India

Rivaroxaban Tablets USP, 2.5 mg had estimated annual sales of $446 million in the U.S.

The company has received EIR from USFDA

This rating reflects Lupin’s leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey

The Board of Directors of the Company, at its meeting held on February 11, 2025, inter alia, considered and unanimously approved the same

Total consolidated income of the increased by 11.38% at Rs 5821.42 crore for Q3FY25

The product will be manufactured at Lupin’s Pithampur facility in India

Bosentan Tablets for Oral Suspension had estimated annual sales of $11 million in the U.S.

The inspection was carried out from January 28, 2025 to February 1, 2025, and concluded with zero 483 observations

This product would be manufactured at the drug firm’s Nagpur facility and will be supplied to low-and middle-income countries

Earlier, the company had signed Share Subscription & Shareholders agreement with Sunsure Solarpark and Sunsure

The EIR was issued with an inspection classification of Voluntary Action Indicated post the inspection of the facility from September 16 to September 27, 2024

The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children

This product will be manufactured at Lupin’s Nagpur facility in India

The affected lot is manufactured at Lupin’s Goa-based manufacturing facility

Total consolidated income of the company increased by 12.52% at Rs 5715.02 crore for Q2FY25

Pred Forte had estimated annual sales of $198 million in the U.S. (IQVIA MAT August 2024)

The inspection was carried out from September 25, 2024 to October 4, 2024, and concluded with five observations

Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America

The inspection closed with three observations each on the API and Finished Product side

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

As per the US Food and Drug Administration, the company is recalling the lot for being ‘Subpotent’

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions of rosacea in adult patients

Valbenazine Capsules, 40 mg and 80 mg had estimated annual sales of $1,621 million in the US

The Board of Directors of the company, at its meeting held on March 22, 2024, has approved the same

The product will be manufactured at Lupin’s Pithampur facility in India

Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S.

Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries

Consolidated total income of the company increased by 20.43% at Rs 5,226.78 crore for Q3FY24

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Goa facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

Varenicline Tablets, 0.5 mg and 1 mg is the generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V

Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

As per the USFDA, the company is recalling the affected lot due to ‘failed dissolution specifications’

The product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies and a team of highly qualified clinical experts

The product will be manufactured at Lupin’s Pithampur facility in India

Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of $33 million in the U.S

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD

The product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Nagpur facility in India

Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region

Total consolidated income of the company increased by 22.08% at Rs 5,078.96 crore for Q2FY24

Rocuronium Bromide Injection had estimated annual sales of $54 million in the U.S.

This product will be manufactured at Lupin’s Pithampur facility in India

The company will have semi-exclusive rights to co-market the product in India under the brand name LINVAS

Diazepam Rectal Gel (RLD Diastat AcuDial) had estimated annual sales of $37 million in the U.S.

This product will be manufactured at Lupin’s Nagpur facility in India

The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’

This product will be manufactured at Lupin’s Pithampur facility in India

Earlier, the company had received approval from board of directors to enter into a business transfer agreement

This product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Somerset facility in the US

This product will be manufactured at Lupin’s Nagpur facility in India

Humrahi, translating to ‘Companion’ is a guide in the journey of diabetes management

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

JAI, a visionary initiative by Lupin, equips patients with the knowledge and skills to manage their condition effectively

This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India

The Board of Directors at its meeting held on September 11, 2023 has approved the same

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life

This product will be manufactured at Lupin’s Pithampur facility in India

Pirfenidone Tablets (RLD Esbriet) had estimated annual sales of $218 million in the U.S.

This acquisition strengthens Lupin’s commitment to providing superior treatment options for patients navigating the complexities of diabetes

With this launch, Lupin introduces an alternative to combat COPD, a condition impacting over 15 million adults in the US and ranked as the fourth leading cause of death in the country

The program includes features designed to encourage healthier lifestyle choices and provides support and care for a healthy heart

Metoprolol Succinate Extended-Release Tablets USP had estimated annual sales of $305 million in the U.S

This product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

The inspection was conducted from August 7 to August 11, 2023

This groundbreaking e-clinic aims to help cardiologists and caregivers manage heart failure patients effectively from the comfort of their homes

Total consolidated income of the company increased by 29.00% at Rs 4,836.89 crore for Q1FY24

This product will be manufactured at Lupin’s Somerset facility in the US

This product will be manufactured at Lupin’s Pithampur facility in India

This comes after the satisfactory evaluation of the corrective actions taken by the company in response to the Warning Letter issued by the USFDA

The subsidiary is for undertaking contract development and manufacturing activities

The product will be manufactured at Lupin’s Pithampur facility in India

This collaboration aims to accelerate the application and adoption of DTx in Cardiology in India

This product would be manufactured at Lupin’s Nagpur facility in India

This launch reflects Lupin’s unwavering commitment to addressing the critical needs of asthma management in Germany

This product will be manufactured at Lupin’s Somerset facility in the U.S

The inspection closed with issuance of a Form-483 with two observations

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

This product will be manufactured at Lupin’s Nagpur facility in India

This product will be manufactured at Lupin’s Somerset facility in the US

The company has achieved a key milestone for its novel MALT1

Rufinamide Oral Suspension had estimated annual sales of $72 million in the U.S

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence

This product will be manufactured at Lupin’s Pithampur facility in India

The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’ (NAI)

Thiamine Hydrochloride Injection USP had estimated annual sales of $35 million in the U.S.

Darunavir Tablets, 600 mg and 800 mg had estimated annual sales of $308 million in the U.S.

Diazepam Rectal Gel had estimated annual sales of $34 million in the U.S. (IQVIA MAT March 2023)

This product will be manufactured at Lupin’s Nagpur facility in India

Cetuximab has received approval from the DCGI for its effectiveness in treating head and neck cancer

Tiotropium Bromide Inhalation Powder (RLD Spiriva) had estimated annual sales of $42 million in Canada

Lupin’s new laboratory at Vijayawada is equipped with state-of-the-art diagnostic technology and staffed by a team of highly qualified clinical experts

Total consolidated income of the company increased by 14.59% at Rs 4,467.35 crore for Q4FY23

With this acquisition, Lupin will gain access to Medisol’s portfolio of seven injectable products across four therapeutic areas

The new laboratory in Bengaluru is equipped with cutting-edge technologies

The inspection closed with issuance of a Form-483 with ten observations

This product will be manufactured at Lupin’s Nagpur facility in India

The inspection closed with no observations

Valbenazine Capsules had estimated annual sales of $1,235 million in the U.S.

The inspection was conducted from March 20, 2023 to March 24, 2023

This product would be manufactured at Lupin’s Pithampur facility in India

Rocuronium Bromide Injection had an annual sale of around $53 million in the U.S.

Thiamine Hydrochloride Injection USP had an annual sale of around $36 million in the U.S.

The study findings were presented at the India Live 2023 symposium in Chennai

The inspection closed without any observation

The inspection was conducted from March 6, 2023 to March 10, 2023 and concluded with no observations

Lupin Diagnostics is committed to making preventive quality healthcare accessible and affordable to all

Lurasidone Hydrochloride Tablets had estimated annual sales of $4.2 billion in the United States

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022

Total consolidated income of the company increased by 3.46% to Rs 4,340.18 crore for Q3FY23

The product marks the first approval from Lupin’s new injectable facility in Nagpur

This product would be manufactured at Lupin’s Nagpur facility in India

LYFE is India’s only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack

The affected lot has been produced at Lupin’s Aurangabad plant

Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg

The product will be manufactured at Lupin’s facility in Goa

NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018

The product will be manufactured at Lupin’s facility in Goa, India

The company has launched this important product under the brand name DIFIZMA in India

To date, Lupin has received no reports of illness that appear to relate to this issue

Lupin Diagnostics currently operates 325+ LupiMitra and 23 laboratories in India

The product will be manufactured at Lupin’s facility in Nagpur, India

RLD PENNSAID had estimated annual sales of $509 million in the U.S.

Rufinamide Tablets (RLD Banzel) had estimated annual sales of $138 million in the U.S.

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $268 million in the U.S.

This move reinforces the company’s commitment to making healthcare solutions accessible to all patients

The inspection of the facility closed with issuance of a Form 483 with eight observations

Total consolidated income of the company decreased by 0.09% to Rs 4,160.46 crore for Q2FY23

Doxycycline Capsules had estimated annual sales of $215 million in the U.S.

Drospirenone Tablets had estimated annual sales of $141 million in the U.S.

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

The inspection closed with issuance of a Form-483 with five observations

Paliperidone Extended-Release Tablets had estimated annual sales of $112 million in the U.S.

The inspection concluded with the issuance of a Form 483 with seventeen observations

The acquisition of these two brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the respiratory therapy area

Through this agreement, Lupin will introduce two new formulations

The product will be manufactured at Lupin’s facility in Nagpur, India

The inspection of the facility was conducted from August 16-19, 2022

The product will be manufactured at Lupin’s facility in Nagpur, India

Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio for Oral Suspension, 10 mg/mL of Viatris Specialty LLC

The USFDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022

The product will be manufactured at Lupin’s facility in Pithampur, India

The company is committed to enhancing patient access to high-quality, life-enhancing biosimilars

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of $202 million in the U.S.

According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval

The company is recalling the affected lot due to Current Good Manufacturing Practice deviations

Dasatinib Tablets (RLD Sprycel) had estimated annual sales of $1569 million in the U.S. (IQVIA MAT June 2022)

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.

Lutio has the potential to offer significant cost savings when available to UK patients

Under the terms of the Agreement, I’rom will conduct clinical trials along with Lupin, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis

The cost of acquisition of brands is euro 26 million

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $282 million in the U.S.

Lupin’s transitioning of the portfolio from the simple generic oral solids to complex generics had started with short-acting bronchodilator albuterol

The product will be manufactured at Lupin’s facility in Goa, India

Total consolidated income of the company decreased by 12.76% at Rs 3,749.40 crore for Q1FY23

Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies for improved patient care

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated

This product will be manufactured at Lupin’s Nagpur facility in India